Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR - ScienceDirect
JCI Insight - Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR - Journal of Cystic Fibrosis
Frontiers | Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis | Bioengineering and Biotechnology
Precision medicine based on CFTR genotype in cystic fibrosis | PGPM
Modulators of CFTR. Updates on clinical development and future directions - ScienceDirect
MidgardFinance.com -
Mechanism of Action | TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Recent Advances in Targeted Genetic Medicines for Cystic Fibrosis | IntechOpen
Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis - eBioMedicine
How It Works | TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
How SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) Works
TRIKAFTA for the Treatment of Cystic Fibrosis, USA
Frontiers | Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies | Pharmacology
Downloadable Materials | TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
How It Works | TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Mechanism of Action | TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
Cells | Free Full-Text | Bicarbonate Transport in Cystic Fibrosis and Pancreatitis | HTML
